Fig. 3
From: Post-symptomatic administration of hMSCs exerts therapeutic effects in SCA2 mice
Treatment with hMSCs downregulates the protein levels of glial-mediated neurotoxic cytokines in the cerebellum of SCA2 mice. A, B Western blot analysis of ionized calcium-binding adaptor molecule 1 (Iba1) and glial fibrillary acidic protein (GFAP) in the cerebellum after 24 weeks of hMSC administration (50-week-old mice). ***p < 0.001 vs. untreated WT mice; ###p < 0.001 vs. untreated SCA2 mice (two-way ANOVA with Tukey’s post hoc analysis; n = 6 for each group). Full-length blots are presented in supplymentary Fig. 5: Fig. 3A. C, D Western blot analysis of tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), and inducible nitric oxide synthase (iNOS) in the cerebellum after 24 weeks of hMSC administration (50-week-old mice). ***p < 0.001 vs. untreated WT mice; ##p < 0.01 and ###p < 0.001 vs. untreated SCA2 mice (two-way ANOVA with Tukey’s post hoc analysis; n = 6 for each group). Full-length blots are presented in supplymentary Fig. 5: Fig. 3C